Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Rheumatoid Arthritis Finding May Lead to New Treatment Options
Disease Discoveries

Rheumatoid Arthritis Finding May Lead to New Treatment Options

By Roger AndersonJan 23, 2014
Share
Facebook Twitter Email
Inflammation and bone destruction are highlighted in the ankle joints of a mouse model with rheumatoid arthritis (RA), left. “When we suppressed IRE1a function through a genetic deletion, the animal models became resistant to RA (at right),” Fang said. 

 

Northwestern Medicine scientists are offering new hope to the millions of people suffering from rheumatoid arthritis (RA).

“What we uncovered is that an enzyme (IRE1a) involved in a completely different biological function is highly activated in macrophage cells from the joint fluid of rheumatoid arthritis patients,” said Deyu Fang, PhD, associate professor in Pathology. “Having defined a novel therapeutic target for the treatment of inflammatory disease, this discovery could have a far-reaching impact.”

The findings were published in the European Molecular Biology Organization (EMBO) Journal. Research associate Quan Qiu was first author.

Rheumatoid arthritis is a chronic debilitating disease of the joints that affects approximately 2 to 3 percent of the world’s population. Because the cells of the immune system play an important role in this chronic inflammatory process, RA is typically classified alongside disorders like lupus as an autoimmune inflammatory disease.

Their shared symptoms mean lupus and RA are often confused for one another. In both disorders, macrophage cells found in bone marrow contribute significantly to the disease.

“Since macrophages are the major source of inflammatory signaling molecules, we wondered whether IRE1a activation is responsible for their production and therefore RA development,” Fang said. “When we suppressed IRE1a function through a genetic deletion, the animal models became resistant to RA.”

Deyu Fang, PhD, associate professor in Pathology, has identified a promising small molecule inhibitor that may treat rheumatoid arthritis. 

 

The discovery puts into question the current theory that a different pathway, NF-kB, plays the dominant role in inflammatory cytokine production. Cytokines are the molecules responsible for inflammatory signaling.

“When we looked at models without IRE1a, we found the expression of molecules in the NF-kB pathway unaltered, yet their production of inflammatory cytokines was largely diminished,” Fang said. “This implies that the role of IRE1a in regulating inflammatory cytokine production is much greater than previously considered.”

The lab will next test the efficacy of small molecule inhibitors that suppress IRE1a activity. Among four recently identified inhibitors, the Fang lab discovered one named 4u8C that largely diminished joint inflammation in mouse models.

“The implication is that pharmacological IRE1a suppression holds great therapeutic potential in RA treatment,” Fang said. “We are also investigating the involvement of elevated IRE1a activation in the development of other inflammatory diseases such as lupus, diabetes and multiple sclerosis to evaluate the potential of IRE1a suppression using genetic and pharmacological approaches as a treatment option.”

The work was supported by National Institutes of Health grants AI079056 and DK083050.

Immunology Research
Share. Facebook Twitter Email

Related Posts

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Comments are closed.

Latest News

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.